You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Distribution of individual antibiotic groups usage in MRSA (18 cases) and MSSA (28 cases) infections

From: Epidemiology, antibiotic consumption and molecular characterisation of Staphylococcus aureus infections – data from the Polish Neonatology Surveillance Network, 2009–2012

Antibiotic groups DOT [%] OR (95%CI) P-value DDD [%] OR (95%CI) P-value
MRSA MSSA MRSA MSSA
Aminoglycosides 17.2 14.9 0.976 (0.697–1.367) 0.967 31.7 28.0 1.366 (1.096–1.704) 0.561
Beta-lactams 6.3 31.7 0.146 (0.092–0.233) 0.005 19.0 40.9 0.338 (0.264–0.435) 0.879
Fluoroquinolones 6.0 0.0 n/a 9.3 0.0 n/a
Glycopeptides 63.6 43.0 2.296 (1.766–2.985) 0.427 33.4 24.9 1.513 (1.208–1.895) 0.533
Lincozamides 2.7 1.1 2.562 (1.008–6.512) 0.221 0.8 1.0 0.775 (0.250–2.408) 0.073
Macrolides 4.2 5.8 0.723 (0.393–1.330) 0.832 2.8 4.4 0.629 (0.348–1.138) 0.072
Trimethoprim/sulfamethoxazole 0.0 3.0 n/a 0.0 0.2 n/a
Metronidazole 0.0 0.5 n/a 0.0 0.6 n/a
Total 100.0 100.0   100.0 100.0  
  1. OR, odds ratio; 95%CI, 95% Confidence Interval; DOT, the aggregate sum of the number of days during which at least 1 dose of antibiotic was received for each one received, days of treatment; DDD, defined daily dose expressed in days; n/a not applicable.